nice PR -- Brilacidin at ICAAC, and glad to see th
Post# of 72440
of late, there's been commentary on how, via new legislation, to improve the FDA's approach to Combo Products -- "drug and/or device and/or biologic and don't fit nicely into existing regulatory pathways, yet comprise roughly one-third of all products in development today."
below some reads. first the best. if B continues to perform thru Ph III, and gains approval, hopefully this door will be opened further, additional Combo applications for B and possibly the PolyCides.
http://thehill.com/blogs/pundits-blog/healthc...s-policies
http://www.mddionline.com/blog/devicetalk/how...s-08-07-15
http://www.fdalawblog.net/fda_law_blog_hyman_...ening.html